Content about Allergy News

03.10.10

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

03.10.10

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

03.10.10

Is it time for all community-based doctors to turn to e-prescribing to cut down on the number of medication errors? According to Rainu Kaushal and colleagues from the Weill Cornell Medical College in New York, electronic prescriptions can dramatically reduce prescribing errors - up to seven-fold.

03.10.10

QLT Inc. today announced results from Phase II clinical trials and a device study for the punctal plug delivery system (PPDS). These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. QLT also announced its plans to expand the program to evaluate a second drug for a new target indication.

03.10.10

With record-setting snowfall and wet weather in the region this winter, one question comes to mind for many as spring approaches: how bad will my allergies be?

03.09.10

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

03.09.10

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

03.09.10

Families with food-allergic children face a life of constant vigilance and the looming fear of life-threatening allergic reactions. This fear can have a huge impact on an entire family's life, from heightened anxiety to severe limits on their daily activities. Some families cope well with this situation, while others find it extremely stressful and difficult to manage.

03.09.10

First Lady Michelle Obama’s “Let’s Move” Campaign tells us that about 32 percent of children and teens (or 25 million) are obese or overweight. It revealed those extra pounds put them at greater risk of developing debilitating and costly diseases including diabetes, high blood pressure and high cholesterol and may also cause them to lead a two to five year shorter life than their parents

01.05.10

Research and Markets has announced the addition of Decision Resources, Inc.'s new report "Strategic Overview of the Immune/Inflammatory Disease Marketplace" to their offering.

01.04.10

Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients.

01.04.10

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has signed a contract potentially totaling up to $143 million to complete the final development, commercial manufacturing and licensure of Anthim, the company's late stage anthrax therapeutic.

01.04.10

InterMune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review designation for the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

01.04.10

Children of parents who refuse vaccines are nine times more likely to get chickenpox compared to fully immunized children, according to a new study led by a vaccine research team at Kaiser Permanente Colorado's Institute for Health Research.

12.31.09

Publix Super Markets is issuing a voluntary recall for Publix Pumpkin Pecan Streusel Pie, because it was mislabeled and may contain undeclared pecans. People who have an allergy or severe sensitivity to pecans run the risk of allergic reaction if they consume this product.

12.29.09

Dr. Oleh Slupchynskyj, Director of The Aesthetic Institute of New York and New Jersey, recently started using Twitter, the popular social networking tool, as a means of disseminating the latest information in facial plastic surgery techniques, new products and beauty trends to his patients and anyone else interested in facial rejuvenation.

10.09.09

With health care reform headed to the floor of the House and Senate, the Aspen Institute and TIME magazine will present a day of panel discussions designed to shed light on what the looming changes will mean for the American people.

10.09.09

Solvay Pharmaceuticals, Inc. announced today that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI).

10.09.09

Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets